Kangfang Biological's IL-4R/ST2 dual antibody approved to conduct 7 Phase II clinical trials for respiratory and autoimmune diseases.

Recently, the National Medical Products Administration approved the initiation of the phase II clinical trials of the world's first bispecific antibody AK139 targeting IL-4R/ST2, developed independently by Kangfang Biotech, for a total of 7 indications including chronic obstructive pulmonary disease, severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic sinusitis with nasal polyps, moderate to severe atopic dermatitis, and nodular prurigo.